Dr. Albert Friesen reports

MEDICURE ANNOUNCES POSITIVE SETTLEMENT OF PRODUCT DEVELOPMENT AND SUPPLY CONTRACTS

A product development and supply contract settlement between Medicure Inc.'s subsidiaries, Medicure International Inc. and Medicure Pharma Inc., and a third party has been reached.

Medicure has received a payment of 1.5 million euros as final settlement. All other terms of the settlement along with the name of the party involved remain confidential.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the company is the marketing and distribution of Aggrastat (tirofiban hydrochloride) injection and Zypitamag (pitavastatin) tablets in the United States, where they are sold through the company's United States subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc., a pharmacy located in North Carolina that offers an extended supply drug program serving all 50 states, Washington, D.C., and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers.

We seek Safe Harbor.